BR0009226A - Método para tratar fibrose em um mamìfero - Google Patents

Método para tratar fibrose em um mamìfero

Info

Publication number
BR0009226A
BR0009226A BR0009226-6A BR0009226A BR0009226A BR 0009226 A BR0009226 A BR 0009226A BR 0009226 A BR0009226 A BR 0009226A BR 0009226 A BR0009226 A BR 0009226A
Authority
BR
Brazil
Prior art keywords
fibrosis
phe
tyr
adhesions
mammal
Prior art date
Application number
BR0009226-6A
Other languages
English (en)
Inventor
James Clagett
Original Assignee
Histatek Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Histatek Llc filed Critical Histatek Llc
Publication of BR0009226A publication Critical patent/BR0009226A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODO PARA TRATAR FIBROSE EM UM MAMìFERO".Processos para tratar fibrose em um mamífero são descritos. Umaquantidade efetiva de antifibróticos de um peptideo que tenha afórmula f-Met-Leu-X, em que X é selecionado do grupo consistindode Tyr, Tyr-Phe, Phe-Phe e Phe-Tyr, é administrada ao mamífero.A fibrose pode ser devida a mudanças patológicas resultantes, porexemplo, de fibrose pulmonar, arterosclerose, cirrose,glomerulosclerose, pancreatite crónica, doença de artéria coronária(tal como a causada pela infecção pela bactéria Chlamydiapneumoniae), trauma ou procedimentos cirúrgicos. Exemplos deprocedimentos cirúrgicos que causam a fibrose são a fibrosepós-operatória perineural na dura ou nas raizes dos nervos emseguida à cirurgia espinhal, tenólise de tendões traumatizados oureparados com aderências, neurólise de nervos periféricosdanificados ou reparados com aderências, aderênciaspós-operatórias oriundas de cirurgias ginecológicas e abdominais,cirurgia reparadora do canal deferente ou tubos de Falópio parareversão da esterilização masculina ou feminina, e reparo cirúrgicode outras estruturas tubulares tais como a uretra, os intestinos ou oesófago.
BR0009226-6A 1999-03-22 2000-03-20 Método para tratar fibrose em um mamìfero BR0009226A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12551499P 1999-03-22 1999-03-22
PCT/US2000/007411 WO2000056349A1 (en) 1999-03-22 2000-03-20 Treatment with small peptides to effect antifibrotic activity

Publications (1)

Publication Number Publication Date
BR0009226A true BR0009226A (pt) 2001-12-26

Family

ID=22420066

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009226-6A BR0009226A (pt) 1999-03-22 2000-03-20 Método para tratar fibrose em um mamìfero

Country Status (18)

Country Link
US (1) US20020072499A1 (pt)
EP (1) EP1162990B1 (pt)
JP (2) JP4021147B2 (pt)
KR (1) KR100699509B1 (pt)
CN (1) CN1348381A (pt)
AT (1) ATE413184T1 (pt)
AU (1) AU3765100A (pt)
BR (1) BR0009226A (pt)
CA (1) CA2367048A1 (pt)
DE (1) DE60040730D1 (pt)
EA (1) EA200100997A1 (pt)
ES (1) ES2316359T3 (pt)
HK (1) HK1045649A1 (pt)
IL (1) IL145490A0 (pt)
MX (1) MXPA01009504A (pt)
NO (1) NO20014594L (pt)
PL (1) PL203758B1 (pt)
WO (1) WO2000056349A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604633B2 (en) 1996-04-12 2009-10-20 Cytyc Corporation Moisture transport system for contact electrocoagulation
US8551082B2 (en) 1998-05-08 2013-10-08 Cytyc Surgical Products Radio-frequency generator for powering an ablation device
WO2001005420A1 (en) * 1999-07-16 2001-01-25 Histatek, Llc Small peptides and methods for downregulation of ige
US7731712B2 (en) 2004-12-20 2010-06-08 Cytyc Corporation Method and system for transcervical tubal occlusion
US7674260B2 (en) * 2005-04-28 2010-03-09 Cytyc Corporation Emergency hemostasis device utilizing energy
US8486060B2 (en) 2006-09-18 2013-07-16 Cytyc Corporation Power ramping during RF ablation
US7846160B2 (en) 2006-12-21 2010-12-07 Cytyc Corporation Method and apparatus for sterilization
CN114463249B (zh) * 2021-11-24 2024-04-05 杭州医派智能科技有限公司 一种基于深度学习的用于评估肾小球周围组织纤维化的辅助方法、计算机设备

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516820A (ja) * 1997-11-13 2002-06-11 ヒスタテク・エルエルシー 低分子量ペプチド及び喘息及び炎症の治療方法

Also Published As

Publication number Publication date
CN1348381A (zh) 2002-05-08
KR20010109316A (ko) 2001-12-08
PL203758B1 (pl) 2009-11-30
US20020072499A1 (en) 2002-06-13
HK1045649A1 (zh) 2002-12-06
NO20014594D0 (no) 2001-09-21
CA2367048A1 (en) 2000-09-28
WO2000056349A1 (en) 2000-09-28
DE60040730D1 (de) 2008-12-18
MXPA01009504A (es) 2003-08-19
IL145490A0 (en) 2002-06-30
JP2002539270A (ja) 2002-11-19
JP4021147B2 (ja) 2007-12-12
ATE413184T1 (de) 2008-11-15
PL350860A1 (en) 2003-02-10
AU3765100A (en) 2000-10-09
EA200100997A1 (ru) 2002-02-28
ES2316359T3 (es) 2009-04-16
NO20014594L (no) 2001-11-21
EP1162990A1 (en) 2001-12-19
EP1162990B1 (en) 2008-11-05
EP1162990A4 (en) 2002-02-06
JP2007131635A (ja) 2007-05-31
KR100699509B1 (ko) 2007-03-26

Similar Documents

Publication Publication Date Title
BR0009226A (pt) Método para tratar fibrose em um mamìfero
Scripcariu et al. Reconstructive abdominal operations after laparostomy and multiple repeat laparotomies for severe intra-abdominal infection
Bloechle et al. A pneumoperitoneum perpetuates severe damage to the ultrastructural integrity of parietal peritoneum in gastric perforation-induced peritonitis in rats
Kongchareonsombat et al. Extraperitoneal versus transperitoneal approach of laparoscopic ureterolithotomy in selected patients
Vara-Thorbeck et al. Laparoscopic ileal-loop conduit
Quah et al. Prospective, randomized trial comparing diathermy excision and diathermy coagulation for symptomatic, prolapsed hemorrhoids
Kotwal et al. Retrospective study of single dose of antibiotic in laparoscopic appendicectomy
Schultz et al. Transabdominal preperitoneal procedure
Mizell Incisions for open abdominal surgery
Becmeur et al. Laparoscopic surgery of Morgagni-Larrey hernias: a multicenter study of the Groupe d'Étude en Coeliochirurgie Infantile (GECI)
PATHANIA et al. Comparative clinical study of complications associated with laparoscopic and open appendicectomy.
Birchak et al. Peculiarities of adhesion process prevention following laparoscopic operations in gynecology
Shamiyeh et al. Effect of hyaluron derivate gel in prevention of postsurgical peritoneal adhesions-an experimental study in pigs
Levent Avtan et al. Video thoracoscopic truncal vagotomies: Technique and preliminary results
Davies et al. Gallstone ileus--beware the silent second stone
RU2680962C1 (ru) Способ симультанного оперативного вмешательства при хроническом калькулезном холецистите в сочетании с пупочной грыжей и диастазом прямых мышц живота
White et al. Laparoscopic mesh repair of recurrent inguinal hernia
SU1232227A1 (ru) Способ лечени звенной болезни двенадцатиперстной кишки
Mangam et al. Study of laparoscopic repair of abdominal incisional hernia
Gurung et al. Laparoscopic inguinal hernia repair (TAPP): early and medium-term results
Afzal " Clinical Outcomes of Laparoscopic Versus Open Appendicectomy" At Al-Ameen Medical College and Hospital, Vijayapur
RU2115368C1 (ru) Способ устранения влагалищного отростка брюшины
Onuma et al. The influence of effective analgesia and general anaesthesia on patients' acceptance of day case varicose vein surgery
Gunay et al. P034 STRANGULATED DIAPHRAGMATIC HERNIA: TEN CASES REPORTS
RU2121305C1 (ru) Способ лечения колоноптоза

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]